These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
187 related articles for article (PubMed ID: 22390210)
1. Reappraisal of the options for colorectal cancer screening in England. Whyte S; Chilcott J; Halloran S Colorectal Dis; 2012 Sep; 14(9):e547-61. PubMed ID: 22390210 [TBL] [Abstract][Full Text] [Related]
2. Comparative effectiveness and cost-effectiveness of screening colonoscopy vs. sigmoidoscopy and alternative strategies. Sharaf RN; Ladabaum U Am J Gastroenterol; 2013 Jan; 108(1):120-32. PubMed ID: 23247579 [TBL] [Abstract][Full Text] [Related]
3. Health benefits and cost-effectiveness of a hybrid screening strategy for colorectal cancer. Dinh T; Ladabaum U; Alperin P; Caldwell C; Smith R; Levin TR Clin Gastroenterol Hepatol; 2013 Sep; 11(9):1158-66. PubMed ID: 23542330 [TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness analysis on screening for colorectal neoplasm and management of colorectal cancer in Asia. Tsoi KK; Ng SS; Leung MC; Sung JJ Aliment Pharmacol Ther; 2008 Aug; 28(3):353-63. PubMed ID: 18638075 [TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of colorectal cancer screening programmes using sigmoidoscopy and immunochemical faecal occult blood test. Senore C; Hassan C; Regge D; Pagano E; Iussich G; Correale L; Segnan N J Med Screen; 2019 Jun; 26(2):76-83. PubMed ID: 30180780 [TBL] [Abstract][Full Text] [Related]
6. Colorectal cancer screening with the addition of flexible sigmoidoscopy to guaiac-based faecal occult blood testing: a French population-based controlled study (Wintzenheim trial). Denis B; Gendre I; Aman F; Ribstein F; Maurin P; Perrin P Eur J Cancer; 2009 Dec; 45(18):3282-90. PubMed ID: 19665368 [TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of the faecal immunochemical test at a range of positivity thresholds compared with the guaiac faecal occult blood test in the NHS Bowel Cancer Screening Programme in England. Murphy J; Halloran S; Gray A BMJ Open; 2017 Oct; 7(10):e017186. PubMed ID: 29079605 [TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of population-based screening for colorectal cancer: a comparison of guaiac-based faecal occult blood testing, faecal immunochemical testing and flexible sigmoidoscopy. Sharp L; Tilson L; Whyte S; O'Ceilleachair A; Walsh C; Usher C; Tappenden P; Chilcott J; Staines A; Barry M; Comber H Br J Cancer; 2012 Feb; 106(5):805-16. PubMed ID: 22343624 [TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness analysis for determining optimal cut-off of immunochemical faecal occult blood test for population-based colorectal cancer screening (KCIS 16). Chen LS; Liao CS; Chang SH; Lai HC; Chen TH J Med Screen; 2007; 14(4):191-9. PubMed ID: 18078564 [TBL] [Abstract][Full Text] [Related]
10. Screening for colorectal cancer: comparison of perceived test burden of guaiac-based faecal occult blood test, faecal immunochemical test and flexible sigmoidoscopy. Hol L; de Jonge V; van Leerdam ME; van Ballegooijen M; Looman CW; van Vuuren AJ; Reijerink JC; Habbema JD; Essink-Bot ML; Kuipers EJ Eur J Cancer; 2010 Jul; 46(11):2059-66. PubMed ID: 20621736 [TBL] [Abstract][Full Text] [Related]
11. Screening based on risk for colorectal cancer is the most cost-effective approach. Dan YY; Chuah BY; Koh DC; Yeoh KG Clin Gastroenterol Hepatol; 2012 Mar; 10(3):266-71.e1-6. PubMed ID: 22100624 [TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness analysis of colorectal cancer screening methods in Iran. Allameh Z; Davari M; Emami MH Arch Iran Med; 2011 Mar; 14(2):110-4. PubMed ID: 21361717 [TBL] [Abstract][Full Text] [Related]
13. Screening and primary prevention of colorectal cancer: a review of sex-specific and site-specific differences. Massat NJ; Moss SM; Halloran SP; Duffy SW J Med Screen; 2013; 20(3):125-48. PubMed ID: 24197771 [TBL] [Abstract][Full Text] [Related]
14. Evaluation of the benefits, harms and cost-effectiveness of potential alternatives to iFOBT testing for colorectal cancer screening in Australia. Lew JB; St John DJB; Macrae FA; Emery JD; Ee HC; Jenkins MA; He E; Grogan P; Caruana M; Sarfati D; Greuter MJE; Coupé VMH; Canfell K Int J Cancer; 2018 Jul; 143(2):269-282. PubMed ID: 29441568 [TBL] [Abstract][Full Text] [Related]
15. Cost effectiveness and projected national impact of colorectal cancer screening in France. Hassan C; Benamouzig R; Spada C; Ponchon T; Zullo A; Saurin JC; Costamagna G Endoscopy; 2011 Sep; 43(9):780-93. PubMed ID: 21623557 [TBL] [Abstract][Full Text] [Related]
16. Screening for colorectal cancer: randomised trial comparing guaiac-based and immunochemical faecal occult blood testing and flexible sigmoidoscopy. Hol L; van Leerdam ME; van Ballegooijen M; van Vuuren AJ; van Dekken H; Reijerink JC; van der Togt AC; Habbema JD; Kuipers EJ Gut; 2010 Jan; 59(1):62-8. PubMed ID: 19671542 [TBL] [Abstract][Full Text] [Related]
18. Strategies in screening for colon carcinoma. de Wijkerslooth TR; Bossuyt PM; Dekker E Neth J Med; 2011 Mar; 69(3):112-9. PubMed ID: 21444935 [TBL] [Abstract][Full Text] [Related]
19. Likely effect of adding flexible sigmoidoscopy to the English NHS Bowel Cancer Screening Programme: impact on colorectal cancer cases and deaths. Geurts SM; Massat NJ; Duffy SW Br J Cancer; 2015 Jun; 113(1):142-9. PubMed ID: 26110973 [TBL] [Abstract][Full Text] [Related]
20. Diagnostic yield in a biennial Hemoccult-II screening program compared to a once-only screening with flexible sigmoidoscopy and Hemoccult-II. Rasmussen M; Fenger C; Kronborg O Scand J Gastroenterol; 2003 Jan; 38(1):114-8. PubMed ID: 12608473 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]